Aurobindo Pharma Bets On Lannett Deal To Fuel US Growth

A 30 percent stock rally can make investors greedy very quickly. Put simply, ₹1 lakh in Aurobindo Pharma at the start of 2026 would be worth about ₹1.30 lakh now, before taxes and charges.

That is a nice return. But the harder question begins here. Has the company already given investors the easy money, or is the bigger story still ahead?

For Aurobindo, that answer now depends on execution. The drugmaker has spent years building new engines. Investors are waiting to see which ones actually start paying.

Lannett adds scale in America

Aurobindo has completed its acquisition of Lannett Company in the US. The deal closed at an enterprise value of about $250 million.

Lannett brings nearly $300 million in annual revenue. For Aurobindo, that matters because the US remains its most important overseas market.

The company reported US revenue of $1.63 billion in FY26. Management wants to take that number to $2 billion over the next few years. Lannett gives it a straight push toward that target.

The price also looks reasonable on paper. Lannett’s revenue moved from $314 million in CY23 to $286 million in CY24, then recovered to $306 million in FY25.

Its Ebitda margin stood at about 15 percent. Ebitda is profit before interest, tax, depreciation and amortisation. Think of it as operating profit before some accounting and financing costs.

That means Aurobindo bought Lannett at below one time sales. It also paid about 5.5 times Ebitda. In market language, that is not a stretched valuation.

The turnaround will decide value

The attraction is clear. But Lannett is not a trophy asset with everything fixed.

It has faced pricing pressure in the US generics market. It has also dealt with product issues and operational problems. These have hurt both growth and profitability.

The US generic drug business is tough. Buyers push prices down. Rival firms copy products fast. One regulatory warning can delay launches and damage margins.

Lannett does have one useful advantage. Its portfolio includes controlled substances and ADHD therapies. These areas usually have higher entry barriers than plain vanilla generics.

That means fewer competitors can enter easily. For a company like Aurobindo, that can protect margins if supply and compliance stay on track.

Lannett’s manufacturing plant can produce about 3.6 billion doses a year. But it now runs at only about 40 percent capacity.

That idle capacity is the opportunity. If Aurobindo fills the plant with more products, revenue can rise without building everything from scratch.

But this is also where investors must stay alert. Turnarounds sound neat in presentations. They become messy on factory floors.

Aurobindo must improve utilisation, clean up operations and use its scale well. If it does that, Lannett’s margin can rise over time.

Margins may feel short-term pressure

The near-term picture may not look perfectly smooth. Aurobindo’s consolidated Ebitda margin in FY26 was around 20 percent.

Lannett’s margin is lower, at about 15 percent. So the acquisition could slightly pull down Aurobindo’s blended margin at first.

Retail investors often miss this point. A deal can be good for growth but still pinch profit margins for a few quarters.

That does not make it a bad deal. It only means the market will watch the integration closely.

The company also expects benefits from Lannett’s distribution network. It can use Lannett’s pipeline and stronger US manufacturing base.

Government business in America is another possible gain. A local manufacturing footprint can help in some supply contracts.

For Indian shareholders, the main issue is simple. Revenue growth must translate into better profit, not just bigger numbers.

If sales rise but margins stay weak, the stock may lose patience. If margins improve, the market may give Aurobindo more credit.

Big investments now face scrutiny

Aurobindo’s current moment did not appear suddenly. The company has spent heavily for years.

Nuvama Research said in a 22 June report that Aurobindo invested ₹11,800 crore in its business over five years. Total capital expenditure stood around ₹15,500 crore.

That money went into several areas. These include Pen-G, injectables, biosimilars, biologics manufacturing and now Lannett.

Pen-G is short for Penicillin G, a key raw material for many antibiotics. India has been trying to reduce dependence on imported drug ingredients.

If Aurobindo’s Pen-G project scales well, it can support growth and improve supply control. That matters in pharma, where input costs can swing sharply.

Biosimilars and biologics are also important. These are complex medicines, often used for serious diseases. They are harder to make than regular tablets.

Because they are difficult, they can offer better margins. But they also need patience, regulatory approvals and steady manufacturing quality.

This is why Aurobindo’s story is changing. It is no longer only about selling more generic pills in America.

It is about whether past spending can become cash flows. Investors have waited through the investment phase. Now they want proof.

Valuation leaves little room

HDFC Securities expects Aurobindo’s consolidated net sales to reach ₹45,000 crore by FY28. That compares with ₹33,700 crore in FY26.

It also estimates an Ebitda margin of 21 percent by FY28. That would mean not just more revenue, but slightly better profitability too.

The growth drivers are clear. They include the Pen-G ramp-up, Lannett integration, new US launches, Europe expansion and higher-margin businesses.

The stock trades at about 17 times estimated FY28 earnings, based on Bloomberg data. That is not cheap enough to ignore execution risk.

After a 30 percent gain in 2026, investors will not reward promises forever. The market will want quarterly evidence.

For a small investor, this is the moment to separate story from delivery. The story says Aurobindo has built several growth engines. Delivery means those engines add profit without surprises.

That is the real test now. Aurobindo has bought scale, built capacity and entered tougher product lines. If management executes well, the rally may have more legs. If not, the stock will remind investors that in pharma, growth always comes with a compliance file attached.